RecruitingNot Applicable

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

United States, Japan400 participantsStarted 2024-03-15

Plain-language summary

It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * A histologically confirmed diagnosis of hepatocellular carcinoma * A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma * Received standard diagnostic and staging procedures as per local guidelines * Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment Exclusion Criteria: * Lack of or inability to provide informed consent * Synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma * Primary liver cancer other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma * Secondary liver cancer

What they're measuring

Sensitivity

Timeframe: Through study completion, an average of 1 year

Trial details

NCT IDNCT06342414

SponsorCity of Hope Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-06-18

Contact for this trial

Ajay Goel, PhD

6262183452 AJGOEL@COH.ORG

View on ClinicalTrials.gov More Hepatocellular Carcinoma trials